Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Tuesday, October 6, 2026

Back to today

Monte Investments Market Brief Vol. CXXX

Golar LNG’s fourth FLNG vessel targets 3.5MTPA capacity and a 2029 delivery, supporting projected adjusted EBITDA above $1 billion in fiscal 2029.

GLNG $4.9B
Monte Independent Investment Research 1 click

From X

@convequity

Convequity on X

The optical engine accounts for over 50% of an optical transceiver's cost, and it contains the most demanding alignment work in the module. For years, engines were built by active alignment: a technician switched on the laser and nudged parts into position until the light coupled. That was workable at 10G, 25G and 100G. At 400G and 800G the tolerances became too tight for manual assembly, and demand driven by AI exceeded what human throughput could supply. $POET's Optical Interposer replaces active alignment with passive assembly. It is a silicon wafer with waveguides and mechanical guides etched into it. Lasers, detectors and electronics are placed on it by automated pick-and-place machines, with nothing powered up during assembly. The parts align passively at the wafer level, much as Lego bricks fit together by their shape. The effect shows up at the transceiver maker. The engine arrives pre-aligned on a standardised substrate, so the remaining assembly looks like conventional electronics manufacturing. Foxconn does that kind of work at high volume, and it was historically locked out of optical transceivers because building them required deep photonic expertise around the engine. Our note's reading is that the interposer takes on the optical complexity so assemblers such as Foxconn, Luxshare, and LITEON do not have to, which helps relieve one of the bottlenecks in optical connectivity for AI clusters.
@KEDM_COM

KEDM.com on X

ProQR Therapeutics $PRQR CEO Daniel de Boer bought $513K across two separate purchases on July 7 and July 9, and a company director bought another $229.5K in late June (real money for a Dutch CEO). PRQR is a small-cap RNA-editing biotech backed by a major pharma partner: Eli Lilly. Their collaboration, running since 2021 and expanded in 2022, could pay ProQR up to $3.75 billion in milestones plus royalties, real validation for a company this size. The balance sheet just got stronger too: ProQR raised roughly $59 million in late June 2026, with Lilly buying in alongside the public offering to keep its stake intact, a vote of confidence from the partner who knows their science best.

Investor Letters

All letters
HWKN · short

Hawkins INC

Hawkins (HWKN) faces margin pressure as cost increases and municipal budget constraints weigh on its water-chemical distribution business.

HWKN $2.8B
Value Investors Club 1 click

Sarepta Risk and the FDA

Sarepta’s Exondys 51 approval despite a 12-patient trial frames FDA regulatory risk and a call to remove Commissioner Robert Califf.

SRPT $1.9B
John Hempton's Newsletter 1 click

Value Roundup

Talen’s post-bankruptcy nuclear assets, FREIT’s $22 Kushner bid and Calithera’s failed liquidation vote illustrate unusual small-cap…

FREVS $118M
Exploring with Alluvial Capital

Publications we follow

Every publication on this site, hand-picked.

128 publications

Newsletters 106

YouTube 4

Blogs 17

Seeking Alpha 46 of 222

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

84 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.